Seborrheic Dermatitis Not Associated With Worse COVID-19 Outcomes

scalp itch dandruff
women head with dandruff Caused by the problem of dirty. Or caused by skin disease or Seborrheic Dermatitis. It has white scaly and it will cause itch. (women head with dandruff Caused by the problem of dirty. Or caused by skin disease or Seborrheic D
The relationship between seborrheic dermatitis (SD) and SARS-CoV-2 in adult patients is examined.

Patients with seborrheic dermatitis (SD) are not at increased risk for severe COVID-19 outcomes, data from a letter to the editor published in the Journal of the European Academy of Dermatology and Venereology suggests. Although immune dysregulation is theorized to play a role in the pathogenesis of SD, a retrospective cohort study found no increased risk for hospitalization, supplemental oxygen therapy, or death in patients with SD at the time of COVID-19 diagnosis.

Investigators reviewed medical records data from patients treated for COVID-19 at George Washington University Hospital in Washington, DC. All patients had received standard-of-care dermatologic examination at intake. Sociodemographic data were compared in patients with and without a diagnosed skin disorder. Multivariable logistic regression models were used to identify correlates of severe COVID-19 outcomes. Models were adjusted for age, sex, race/ethnicity, insurance status, smoking history, and comorbid medical conditions.

The analytic cohort included 430 adults with COVID-19, among whom 9.1% had a diagnosis of SD. In regression models, SD was not associated with the risk for hospitalization due to COVID-19 (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.08-0.86; P =.17), nor with the risk for requiring oxygen therapy (OR, 0.26; 95% CI, 0.06-1.09; P =.23). Patients with SD were not more likely to have severe/critical COVID-19 compared with patients without SD (OR, 0.72; 95% CI, 0.27-1.90; P =0.79) and did not have longer hospital stays (OR, 0.36; 95% CI, 0.03-4.08; P=0.79). Also, no evidence suggested that patients with SD were at increased risk for lingering COVID-19 symptoms or death (both P >0.99).

Study limitations include the lack of data on SD characteristics; further study of COVID-19 outcomes in patients with dermatologic conditions is warranted.

The data suggest that SD does not increase risk for severe COVID-19 outcomes, despite its underlying association with immune dysregulation, the investigators wrote.


Rakita U, Kaundinya T, Guraya A, et al. Lack of association between seborrheic dermatitis and SARS-CoV-2 outcomes. J Eur Acad Dermatol Venereol. Published online November 22, 2021. doi:10.1111/jdv.17825